1-3 of 3
Richard Quek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study

Available to Purchase
Albiruni R. Abdul Razak, Sebastian Bauer, Cristina Suarez, Chia-Chi Lin, Richard Quek, Marie Luise Hütter-Krönke, Ricardo Cubedo, Stephane Ferretti, Nelson Guerreiro, Astrid Jullion, Elena J. Orlando, Giorgia Clementi, Janna Sand Dejmek, Ensar Halilovic, Claire Fabre, Jean-Yves Blay, Antoine Italiano
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1087–1097.
https://doi.org/10.1158/1078-0432.CCR-21-1291
Published: 14 March 2022
View article titled, Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Open the PDF for Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

High-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) for patients with relapsed, primary refractory or intermediate and high risk aggressive non-hodgkin’s lymphoma (NHL) treated in the Department of Medical Oncology, National Cancer Centre.

Free
Miriam Tao, Soon Thye Lim, Richard Quek, Siew Wan Hee
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22_Supplement): C28.
Published: 15 August 2014
View article titled, High-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) for patients with relapsed, primary refractory or intermediate and high risk aggressive non-hodgkin’s lymphoma (NHL) treated in the Department of Medical Oncology, National Cancer Centre.
Journal Articles

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

Free
Richard Quek, Qian Wang, Jeffrey A. Morgan, Geoffrey I. Shapiro, James E. Butrynski, Nikhil Ramaiya, Tarsha Huftalen, Nicole Jederlinic, Judith Manola, Andrew J. Wagner, George D. Demetri, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 871–879.
https://doi.org/10.1158/1078-0432.CCR-10-2621
Published: 15 February 2011
View article titled, Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
Open the PDF for Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors in another window